z-logo
open-access-imgOpen Access
Seroprevalence of the Human T Lymphotropic Virus (HTLV 1 and HTLV 2) in Blood Donor Candidates in the State of Pará, Northern Brazil
Author(s) -
Carolina de Alcântara Maneschy,
Katarine Antônia dos Santos Barile,
Jairo Augusto Américo de Castro,
Maurício Koury Palmeira,
Renata Bezerra Hermes de Castro,
Carlos Eduardo de Melo Amaral
Publication year - 2022
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v11i4.27082
Subject(s) - seroprevalence , serology , medicine , population , human t lymphotropic virus , etiology , transmission (telecommunications) , immunology , demography , virology , environmental health , antibody , electrical engineering , myelopathy , psychiatry , sociology , spinal cord , engineering
The present study describes HTLV seroprevalence in potential blood donors from the Brazilian state of Pará, and the sociodemographic characteristics of the infection in this state. This descriptive, retrospective, and cross-sectional study is based on secondary serological and sociodemographic data on potential blood donors who were rejected for presenting reactive results in the serological HTLV screening between January 2010 and December 2020. The mean HTLV seroprevalence was 0.2%. The highest frequency of reactivity was recorded in first-time donors, women, individuals over 30 years old that were single and had a relatively low level of  education. There have been many advances since the discovery of HTLV, although it is still considered to be a neglected etiological agent in Brazil. Further research on data from hematological services will be necessary to refine regional infection profiles, which will be fundamental for the development of adequate prophylactic practises to control and prevent infection, as well the dissemination of information on the dangers of HTLV to the general population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here